Clinical studies indicate that MPC expression affects cancer treatment efficacy; in hepatocellular carcinoma, inhibiting the peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC1α)/nuclear respiratory factor (NRF1)-MPC axis increases sensitivity to sorafenib and doxorubicin [46]. This evidence concerns the gene PPARGC1A and hepatocellular carcinoma.